References
- Dalton L K, Demeac S, Elmes B C, et al. Synthesis of the tumor-inhibitory alkaloids, Ellipticine, 9-methoxyellipticine and related pyrido (4′3–6) carbazoles. Aust J Chem 1967; 20: 2715–2727
- Svoboda G H, Poore G A, Montfort M L. Alkaloids of Ochrosia maculata Jacq. (Ochrosia borbonica Gmel.): Isolation of the alkaloids and study of the antitumor properties of 9-methoxy ellipticine. J Pharm Sci 1968; 57: 1720–1725
- LePecq J-B, Dat-Xuong N, Gosse C, et al. A new antitumoral agent: 9-hydroxyellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. Proc Nat Acad Sci USA 1974; 71: 5078–5082
- Paoletti C, Cros S, Dat-Xuong N, et al. Comparative cytotoxic and antitumoral effects of ellipticine derivatives on mouse L1210 leukemia. Chem Biol Interactions 1979; 25: 45–58
- Mathe G, Hayat M, De Vassal F, et al. Methoxy-9-ellipticine lactate. III-Clinical screening: its action in acute myeloblastic leukemia. Rev Eur Etud Clin Biol 1970; 15: 541–545
- LePecq J-B, Gosse C, Dat-Xuong N, et al. Two new antitumor derivatives: hydroxy-9-methyl-2-ellipticinium (acetate) and hy-droxy-9-dimethyl-2, 6-ellipticinium (chloride). Activity in L1210 leukemia in mice. (Translation). CR Acad Sci (Paris) Series D 1975; 281: 1365–1367
- Herman E H, Chadwick D P, Mhatre R M. Comparison of the acute hemolytic and cardiovascular actions of ellipticine and some ellipticine analogs. Cancer Chemo Rep 1974; 58: 637–643
- Cros S, Sorbara R, Moisand C, et al. Toxicological and pharmacological studies on 9-hydroxyellipticine in mice. Toxicol Appl Pharmacol 1975; 33: 484–497
- Juret R, Heron J F, Couette J E, et al. Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: A 5-year experience. Cancer Treat Rep 1982; 66: 1909–1916
- Brugarolas A, Gracin M, DeJager R, et al. 9-hydroxy methyl ellipticinium (9 HME, NSC 264137): Phase I clinical study. Am Assoc Cancer Res 1979; 20: 77
- Amiel J L, LT 50,100. Study of clinical tolerance in diverse forms of cancer and of efficacy on metastases from cancers of the breast. Sanofi Report
- Claysse A, Brugarolas A, Siegenthaler P, et al. Phase II study of 9-hydroxy-methyl-ellipticinium in advanced solid tumors. Am Assoc Cancer Res 1980; 21: 348
- Amiel J L, LT 50,100. Study of antitumor activity and tolerance. EORTC Phase II Sanofi Report
- Criel A M, Hidajat M, Clarysse A, et al. Drug dependent red cell antibodies and intravascular hemolysis occurring in patients treated with 9-hydroxy-methyl-ellipticinium. Br J Haem 1980; 46: 549–556
- Homberg P. July, 1980, LT 50,100 Report in immunoallergic hemolytic accidents due to ellipticine. Sanofi Report
- , LT 50,100 general survey. Renal tolerance of elliptinium acetate. Sanofi Report
- Jones B R, Bhalla R B, Mladek J, et al. Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther 1980; 27: 557–562